Hormonal treatment of advanced breast cancer. (Q40931762)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8535909 AND SRC:MED&resulttype=core&format=json

14 October 2019

review article

1 reference

title

Hormonal treatment of advanced breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8535909 AND SRC:MED&resulttype=core&format=json

14 October 2019

author name string

Tellez C

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8535909 AND SRC:MED&resulttype=core&format=json

14 October 2019

Jordan VC

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8535909 AND SRC:MED&resulttype=core&format=json

14 October 2019

publication date

1 October 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8535909 AND SRC:MED&resulttype=core&format=json

Surgical oncology clinics of North America

14 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8535909 AND SRC:MED&resulttype=core&format=json

14 October 2019

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8535909 AND SRC:MED&resulttype=core&format=json

14 October 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8535909 AND SRC:MED&resulttype=core&format=json

14 October 2019

page(s)

751-777

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8535909 AND SRC:MED&resulttype=core&format=json

Japanese early phase II study of droloxifene in the treatment of advanced breast cancer. Preliminary dose-finding study

14 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Treatment of metastatic breast cancer patients with different dosages of megestrol acetate; dose relations, metabolic and endocrine effects.

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

European early phase II dose-finding study of droloxifene in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

The risk of breast cancer after estrogen and estrogen-progestin replacement

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Aromatase inhibitors and the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Aromatase inhibitors--mechanisms of steroidal inhibitors

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Biochemical and molecular aspects of aromatase

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

1 reference

7 January 2021

A risk-benefit assessment of tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Progesterone receptors and human breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

First generation aromatase inhibitors--aminoglutethimide and testololactone

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Tamoxifen and arterial thrombosis

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Inhibition of adrenal corticosteroid synthesis by aminoglutethimide: studies of the mechanism of action

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Tamoxifen treatment of metastatic breast cancer and antithrombin III levels

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Pharmacologic and biologic properties of droloxifene, a new antiestrogen.

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Current perspectives on aromatase inhibitors in breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Influence of Synthetic Oestrogens on Advanced Malignant Disease

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Phase I study of toremifene in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

A phase I trial of toremifene, a new antiestrogen

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

A new derivative of triphenylethylene: effect on implantation and mode of action in rats

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Preclinical data for Droloxifene

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Breast cancer and the oestrogen window hypothesis

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Do regular ovulatory cycles increase breast cancer risk?

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Experience with aromatase inhibitors in the treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Predicting Response to Endocrine Therapy in Human Breast Cancer: A Hypothesis

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

A phase III trial of oral high-dose medroxyprogesterone acetate (MPA) versus mepitiostane in advanced postmenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

DES versus tamoxifen in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Mechanism of Action of the Female Sex Hormones

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

A new triphenylethylene compound, Fc-1157a. II. Antitumor effects.

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Review of the pharmacological properties of toremifene

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Comparison of tamoxifen and hypophysectomy in breast cancer treatment

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Tamoxifen (antiestrogen) therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Specific binding of estrogen receptor to the estrogen response element

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Oestrogen-receptor status and endocrine therapy of breast cancer: response rates and status stability

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Endocrine and clinical effects of an LHRH analogue in pretreated advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Antioestrogens in the management of hormone-dependent cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Prognostic factors for recurrence and survival in axillary node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Phase II clinical study of toremifene in patients with metastatic breast cancer. Preliminary communication

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Phase II clinical study of high-dose toremifene in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Treatment of breast cancer with medroxyprogesterone acetate

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Tamoxifen (Nolvadex) versus adrenalectomy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Rebound response after estrogen therapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

The value of estrogen and progesterone receptors in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Action of "pure" antiestrogens in inhibiting estrogen receptor action

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

4-hydroxyandrostenedione--further clinical and extended endocrine observations

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Arimidex: a potent and selective fourth-generation aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Droloxifene, a new antiestrogen: its role in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Pituitary and gonadal desensitization after continuous luteinizing hormone-releasing hormone infusion in normal females.

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Treatment of advanced breast cancer with tamoxifen

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC Breast Cancer Co-operative Group Trial (10792)

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Gonadotropin releasing hormone (GnRH) analogs for the treatment of breast and prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Suppression of estrogens with Aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: A review

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Aspects of hypothalamic regulation of the pituitary gland

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A.

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Aminoglutethimide in the treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Tamoxifen in premenopausal patients with metastatic breast cancer: a review

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Detection of estrogen receptor in breast and endometrial carcinoma by the immunoperoxidase technique

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Survival of women with metastatic breast cancer at Yale from 1920 to 1980

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

A receptor molecule for estrogens: studies using a cell-free system

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Predictive value of tumor estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Aromatase inhibitors--mechanisms for non-steroidal inhibitors

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Biology and mode of action of pure antioestrogens

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist D-Ser(But)6Azgly10LHRH in premenopausal women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Synthetic oestrogens in mammary cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

The treatment of postmenopausal women with advanced breast cancer with buserelin

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Pharmacology of vorozole

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

Vorozole, a specific non-steroidal aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1016/S1055-3207(18)30428-9

7 January 2021

10.1016/S1055-3207(18)30428-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8535909 AND SRC:MED&resulttype=core&format=json

14 October 2019

1 reference